Takeda files alogliptinand Actos NDA in USA

Takeda Pharmaceutical's US subsidiary has filed s a New Drug Application with the Food and Drug Administration for alogliptin (SYR-322)/Actos (pioglitazone) for the treatment of type 2 diabetes. Alogliptin is a member of the DPP-4 inhibitors class, which are newer oral agents for the treatment of this disease, in which the body does not efficiently use the insulin it produces to control blood glucose levels. "Alogliptin/Actos, if approved, will be the first type 2 diabetes treatment option which includes a DPP-4 inhibitor and a TZD," commented Takeda president Yasuchika Hasegawa.